Archive for July 5th, 2010
Preclinical development of monoclonal antibodies and Biologicals: new technologies and new cancer treatments
Monoclonal antibodies are the segment of the pharmaceutical industry, with annual income expected dollars over the next few years up four. antibodies power 23 full-size monoclonal and three fragments of monoclonal antibodies were derived much more swiftly achieve blockbuster position (annual income of over € bn). Between 1995 and 2007, indicating the number of drug candidates monoclonal antibody-based clinical trials more than tripled, and this expansion continues.
This report explains that the monoclonal antibody, and why the huge pharmaceutical companies as major investments in both internal drug development and acquisition of other monoclonal antibody candidates. More than 80 favourite and new technologies are identified, explained and illustrated with original drawings in color. The last wave of drug candidates based on these technologies can, in more than 200 case studies, which are all commercial enterprises known in preclinical studies of therapeutic monoclonal antibodies in the last year conducted a piece of identity. Finally, prospects and challenges for the future of this area are discussed, with comments from the pioneers of science and industry leaders. The main features of this report• Beginners illustrated guide “to monoclonal antibodies. What they are, how they are doing and why they hold so much promise for disease treatment
• More than 80 descriptions of patented technology being used worldwide to produce and re-engineered monoclonal antibodies.
• Over 30 original scales colors, where science and technology of monoclonal antibodies, as they were both in nature and in countless new forms currently in preclinical studies. think about this report• Understanding basic properties of monoclonal antibodies and how these qualities translate into one-of-a-kind functions for medical and commercial product candidates.
• Enjoy the challenges and risks of monoclonal antibodies as well as its promise. • To evaluate promising new technologies for investment or licensing. • Identify businesses in this area involved, and what they do. • E-type drug use, clinical trials in the next 1-4 years in power and can reach the market in the next 5-10 years. is the key market questions
• New monoclonal antibodies, new disease processes, which is not currently addressed by other therapies targeting the areas of access to markets with high demand.
• The inherent specificity and predictability of monoclonal antibody has been shown to reduce drug development and increase the success rate of pre-clinical and clinical versus non-organic “small molecule” drugs. •prevent barriers to entry are now many new companies entering the area. The techniques used this day to create, edit or choose monoclonal antibodies for therapeutic use rights are fortified by intellectual property rights, the authors defend vigorously protected. However, some patents from the beginning of the basic techniques very soon.
The main conclusions of this report• Early challenges immunogenicity, tissue penetration, management and production of monoclonal antibodies to treat the new technologies.
• The competitive advantage to refer and address new therapeutic targets continue to attract new target selection and finding of monoclonal antibodies offer programs. • Implementation techniques for “humanizing” the favourite non-human monoclonal antibody as before, despite the current rise of “fully human” monoclonal antibody technologies. This might be due to the robustness of the technology early and / or the immediate process of key patents. • The methods of genetic engineering and novel host cell systems of production “will optimize and alter the functions used by monoclonal antibodies. Proprietary platforms of these methods have been widely licensed to many the main players in the biopharmaceutical industry. Key issues answered• What are monoclonal antibodies, and what can he do?
• Why so many companies developed as therapeutic agents • Which companies are currently working to validate and develop the next generation of drug candidates based on monoclonal antibodies • What are the technological and regulatory challenges that companies in the development of these candidates, and market drugs Index:Summary 16
An introduction to the monoclonal antibody 16
not refer human monoclonal antibody-17
optimize long-term antibody 17
human monoclonal antibody 18
conjugated antibody-19
20-binding antibody molecules Novel p derived
Chapter 1 Introduction to the monoclonal antibody 22
Summary 22
Introduction 23
antibodies in kind 23 benefitsmonoclonal antibodies as drugs 29
target range of 29
predictability 30
Pharmacokinetics 30 30
Challenges and opportunities for the next generation of monoclonal antibodies 31
Target Selection 31
33 species specificity
Pharmacokinetics 34
Make 34
monoclonal antibody drugs already on the market 35
Orthoclone OKT3 35
Remicade 36
Rituxan 36
Zenapax 37
Synagis 37
Humira 37
Vectibix 38
Simponi 38
Lucentis 38
Cimzia 39
Tysabri 39
The preclinical development of therapeutics 40
p Proof of Concept 40
Security Profile 40
42
Chapter 2: Identification of non- human monoclonal antibody-46
Summary 46
Introduction 47
Technology Platforms 47
Hybridoma 48
RabMAbs 48
SLAM 48 </p
> Platform answer man 49
DIAAD 49
ImmuneY2 50
IMAB 50
Fusion Expression Technology 51 </p
Wed ProMIS 51
AbScreen 51
AbProt 52
BioArctic platform 52
FunctionFIRST 52> </p case studies 52
Abbott Labs 53
AbGenomics 53
Alethia 53
Amorfix 53
Arrowsmith Technologies 54
AVEO 55
BioSceptre 55
Canadian Bio Med Systems 55
Cangene 56
CellAct 56
Sea 57
Crucell 57
CSL 58
Daewoong 58
DKFZ 58
Epitomics 59
Antibody Fusion 59
Ganymed Pharmaceuticals 60
GeNeuro 60
Genitope 60
GSK 61
61
Immuno-Biological Laboratories, 61
ImmunoGen 62
Immutep 62
InflaRx 63
Innate Pharma
63
Inotek 63
Intercell 64
LigoCyte 64
MedImmune 64
Morphotek 65
NeoGenix 65
Biotherapeutics Northwest 66
Novartis 66
Novo Nordisk 67
OncoMed 67
Therapeutics 67
Pfizer 68
Pharma Research of Toronto 69
Biotech 69
69
Biopharma Recepta 69
70
Roche 70
Shanghai CP Guojian 71 Stainwei 71
Thera Pure 71
ThromboGenics 71
Thrombotargets 72
Tolerx 72
Trillium 73
Vaccinex 73
Wilex 73
ZymoGenetics 74
Conclusions 81
Chapter 3 Optimization of long-term antibody 84
Summary 84
Introduction 85
Plates technological platforms 86
chimeric antibodies 86
CDR-grafting 88
SMART 90
Superhumanisation 90
Patching Frame 91
Composite Human Antibodies 91
Atlab 92
Humaneering 92
MLG 93
DeImmunisation 93
Humana 93
Engineering man 94
FCX 94
Lex system 94
POTELLIGENT 94
Complegent 95
BestMAb 97
ImmunoBody 97
EB66 97
Platform expression Synageva 98
XmAb 98 p Engineered Antibody 99
Wox 99 Wed case 101
Abbott Labs 101
Advanced immunotherapy 102
Alder Biopharm 102
Alethia 103
Alexion 103
Antisoma 103
Arana 104
mitigate 105
AVEO 106
Neuroscience BioArctic 106
Biogen Idec 106
Biolex 107
BioXell 108
China Synthetic Rubber Corp. 108 108
CSL
CureTech 109
Direvo 109
DSX 109
Eli Lilly 110
Epitomics 110
Faron Pharm
110
Pharm Femta 110
Forerunner Pharma Research 111
Antibody Fusion 111
Galaxy Biotech 112 </
p> Wed uranologist Oncologic 112
Genentech 113
Glenmark 113
glycoform 114
glycotope 114> </p ImmunoCellular Therapeutics 114
Immunomedics 115
Innate Pharma 115
InNexus Biotech 115
Intellect Neurosciences Isu 116
Abxis 116
Janssen Alzheimer immunotherapy 116
KaloBios 117
Keel Pharm 117
LigoCyte 117
Lpath 117
Mabion 118
MacroGenics 118
MaimoniDex 119
MAT Biopharma 119
MedImmune 119
Medtronic 120
Micromet 120
NKT Therapeutics 120
Opsona 121
Percipio 121
Pharma Search Toronto 122
ProTAB 122
Scan Cell 123
seleXys 123
Bioscience SinoMab 124
Synageva 124
TaiMed 124
Trillium 125
Biomedical United 125
Vascular 125
VasGene 126
Vegenics
126
Vybion 126
Xencor 127
Conclusions 134
Chapter 4 fully human monoclonal antibody 138
Summary 138
Introduction 139
139 technology platforms
phage-display-139
MBAS 141 p SAMC 142
HuCAL 142
isolated from these 142
ActivMAb 143
Adimab platform 143
XenoMouse 143
UltiMAb 145
VelocImmune 145
Open monoclonal technology 146
Xenerex 146
SEBVI 147
cloning the human response 147
platforms Viventia 147
natural human antibodies 148
MabIgX 148
Reverse Translational Medicine 148
I STAR-149
instead of cells 149
iBioLaunch 149
Case Studies 150
Adimab 150
Acorda Therapeutics 150
Affitech 151
Agensys 153
Alopexx 153
AstraZeneca 154
BioFactura 155
Biotherapix 156
CellAct 156
Celldex 156
Centocor 157
Crucell 158
CSL 158
Dyax 158
Emergent BioSolutions 158
Functional Genetics 159
Genmab 159 </p
> Wed Crucell 160
GSK 160
HuMAb 160
Antibodomics human 161
Humanyx 161
Ibio 162
ImClone 162
IMED Therapeutics 163
Immune System 163
IQ Therapeutics 164
Kenta Biotech 164
Kyowa Hakko Kirin 165
MabVax 165
Mapp Biopharmaceutical 166
Medarex 166
MedImmune 167
Merck & ; Co 168
Micromet 169 169
NatImmune 170
Neurimmune 170
NovImmune 170
Novo Nordisk 171
Omeros Corp. 172
Oncaidia 172
OncoMed 172
Oxford BioTherapeutics 173
Panacea 173
patrys 174
Peregrine 175
PharmAbcine 176
sanofi-aventis 176
Thera Clone 177
Trellis Bioscience 178
U3 Pharma 178
Vaccinex 179
Vegenics 179
Wed Xoma 180
Conclusions 189
Chapter 5 antibody conjugated 192 </ / p> Summary 192
Introduction 193
193 technology platforms
Antibody drug conjugate 193
antibodies payload 195
This Probo 195
Antibody Cloaking 197
targeted photodynamic therapy 197
AlbudAb 198
hyFc 198
ligand traps 198
CovX-body 200
dynamic linking 200
LEC technology 200
Case Studies 201
ALGETA 201
Aphios 201> </p Technologies ArmaGen
201
Medical Center Asan 202 Bayer
Schering 202
Beijing ABT 203
Biogen Idec 203 </p
> Wed biotransformations 203
Boehringer Ingelheim 204
Celldex 204
Cytoguide 205
CytomX 205> </p Dompé 206
EnGeneIC 206
FDA 206
Forerunner Pharma Research 207
Oncologic uranologist 207
Genentech 207
Genexine 208
ImmunoGen 208
Immunomedics 209
InNexus Biotech 210
Medarex 210
MedImmune
211
Merrimack 211
Morphotek 212
Mycenax 212
212 NCI
Oncaidia 213
oncotherapy Science 213
Panacea 214
Peregrine 214
Pfizer 214
Pivotal BioSciences 215
Seattle Genetics 215
Symphogen 215
216
Viventia 216 222
Chapter 6 new molecules of antibody binding 224 </> p / derivatives
Summary 224 Introduction 225 226 technology platforms Fab 226 TetraMABs 227 scFv 227 Immuna 228 [scFv] 2228 BiTE 229 </p Avibodies My 230 TandAb 233 Flexi Body 234 V-NAR 234 Nanobodies 236 p domain antibodies> 238 heteropolymer 242 UniBody 243 field of anti-trade 244 246 SMIP> </p SCORPION 247 DVD-Ig-248 249 case studies Abbott Labs 249 Ablynx 249 Adaltas 250 Affimed 250 Avipep 251 Beijing ABT 251 Biogen Idec 252 Calmune 252 Elusys 253 ESBATech 253 253 glycotope 254 GSK 254 Inmunova 255 256 Micromet 256 257 PharmAbcine 257 Trubion 257 Suzhou Stainwei Biotech 258 Taligen 259 Vegenics 259 Conclusions 264 Research Methodology Primary
266 Glossary 267 278 Index <p over reports of sand, prefabricated up of an online library of 10,000 reports, detailed market studies market statement over 5000 websites and 25 industry-specific. Articles More technology article
articlesbase.com
Information Technology

IT defines as Information Technology, IT is consists of study, design, advance development, accomplishment, support or administration of personal foundation information system, mostly software application and personal hardware. Information technology works with the use of electronic personal and personal software to renovate, defend, development, and broadcast and other information.
Information technology has overstuffed to cover many features of computing and technology, and this word is more familiar than ever before. Information technology subject can be quite large, encompassing many fields. IT professionals perform different types of responsibilities that range from installing applications to designing complex personal networks. IT professional’s responsibilities are data management, networking, database, software design, personal hardware, management and administration of whole system. IT (Information Technology) is combined word of personal and communications or “InfoTech”. Information Technology illustrates any technology which helps to manufacture, manipulate, accumulate, communicate or broadcast information.
Information Communications Technology (ICT):- ICT term comprises the entire technology for communication of advance information. It includes any intermediate to record information by paper, attractable disk or tape, pen, optical disks, flash memory, CD/DVD etc. and also ICT technology used for broadcasting information by television, radio, microphone, loudspeaker and cellular phones. Information technology transfer information with the help of satellite system and intercontinental cables. Defiantly IT has developed into a type of a hub for communicating information.
Informative modeling: – it is an interdisciplinary myth for connecting information technologies field with architectural examination and modeling. IM aspires at improving the way evidences and information about architectural objects developed throughout time can be demonstrated. IM applies for studying of historic architecture, and objects been broadly transformed.
Technical support: – it is a range of services which has provided by technology products as mobile cell phone, TV and personal or electronic & mechanical gadgets. Technical services attempt to assist the individual resolve specific problems with the product. Somewhat that offering training, support services and other customization.
Most of the companies advocate technical support on behalf of the products, either they are freely acquirable or for a pay. Technical support can be conveyed by the telephone or with the help of various channels like e-mail or a website. Major organizations having frequently internal technical service acquirable to staff for pc related problems. Also world wide web is the ideal place to convey your problem in form of message and it’s freely acquirable for tech support, where many of experienced users might advice and assistance you.
Yissum And Technology Transfer At The Hebrew University Of Jerusalem

Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, aims to promote the transfer of Hebrew University technology for the benefit of society, while maximizing returns to support research, education and scientific excellence.
Founded in 1964, Yissum is one of the first technology transfer companies worldwide – second only to the Weizmann Institute’s Yeda, founded in 1959, and many years senior to most American universities – which began their Technology Transfer Services activities following the Baye-Dole Act of 1980; European universities, which typically began these activities in the 1990’s and Japan, which only began in 1998.
Yissum provides the interface between the university’s researchers and industry, including:
· Licensing out of new technologies
· Creation and support of spin-off companies
· Industry-sponsored academic research
· Scientific services
These years of experience have borne fruit, as Yissum’s revenues place it among the top 15 universities worldwide. Close to $1 billion worth of products based on Hebrew University technology are sold worldwide annually. Yissum’s 2005 revenues were $35 million, of which $23. 5 million in royalties Through its efforts in securing industry-sponsored research and other funding, Yissum contributes some 10% of the Hebrew University’s research budget, making the institution a true Technology Transfer University.
Charged with the endorsement and commercialization of the university’s intellectual property, Yissum has generated over 1,500 patent families over the past 20 years alone, of which 750 are currently active, including 250 which are licensed. In addition, Yissum holds equity in over 50 companies. In 2007, Yissum received 121 disclosures, submitted 91 patent applications and was allowed 59 new patents worldwide.
On the commercialization side, over 400 projects were handled in 2007 and 418 agreements were signed, including 33 license and option agreements.
Yissum enjoyed the first Initial Public Offering of one of its companies on the Tel Aviv stock exchange in December 2005 when NasVax Ltd. , based on technology from Prof. Chezy Barenholz, was successfully floated. The company now has $10 million in the bank and is in clinical trials with its influenza vaccine. This is not the first commercial success for Prof. Barenholz, who is also the developer of Doxil, sold by Johnson & Johnson (through its acquisition of Alza) in the United Says and Schering Plough (under the trade study Caelyx) internationally. Doxil enjoyed worldwide income of over $400 million in 2005.
Yissum, through the creation of Atox Bio Inc. , was also chesty to sponsor the submission to the NIH of a allow application by Prof. Raymond Kaempfer, who successfully received US$ 5. 6 million for the biodefence applications of super-antigens. Yissum continues to support AtoxBio as it develops other applications of Prof Kaempfer’s technology.
BioCancell Inc. , which was highlighted in last year’s report, successfully raised over US$3 million from private investors and the Hebrew University’s pension fund (as an independent investor), and successfully began clinical trials with its H19-based therapy in patients suffering from bladder cancer.
Following a change of management at the end of 2005, Yissum has announced some organizational changes aimed at providing the university’s researchers with better, more focused service. In addition, Yissum is in the process of simultaneously identifying the university’s Top 30 most commercially-attractive projects, and at the same time raising funds to invest in taking these projects through the proof-of-principle phase in order to achieve significantly higher valuations and much better terms for commercialization. 2006 promises to be an exciting year for Yissum.
Yissum is the Technology Transfer Company of the Hebrew University of Jerusalem. Over the past 40 years, Yissum has allowed more than 400 technology licenses and is responsible for commercializing successful products that generate almost $1 billion in worldwide income each year.